Publisher Correction: Contextual determinants of TGFβ action in development, immunity and cancer (Nature Reviews Molecular Cell Biology (2018) DOI: 10.1038/s41580-018-0007-0);Contextual determinants of TGFβ action in development, immunity and cancer

Nature Reviews Molecular Cell Biology

Volumn 19, Issue 7, 2018, Pages 419-435

  David, Charles J ^a,b   Massagué, Joan ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

LIGAND; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

CARCINOGENESIS; CELL DIFFERENTIATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; IMMUNOREGULATION; MALIGNANT NEOPLASM; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL; T LYMPHOCYTE SUBPOPULATION; TGF BETA SIGNALING; TUMOR IMMUNITY;

EID: 85045202500     PISSN: 14710072     EISSN: 14710080     Source Type: Journal    
DOI: 10.1038/s41580-018-0018-x     Document Type: Erratum

References (195)

1. Massagué, J. How cells read TGF-beta signals. Nat. Rev. Mol. Cell Biol. 1, 169-178 (2000).
2. Josso, N., Belville, C., di Clemente, N. & Picard, J. Y. AMH and AMH receptor defects in persistent Mullerian duct syndrome. Hum. Reprod. Update 11, 351-356 (2005).
3. Lindsay, M. E. & Dietz, H. C. The genetic basis of aortic aneurysm. Cold Spring Harb. Perspect. Med. 4, a015909 (2014).
4. Matzuk, M. M. & Burns, K. H. Genetics of mammalian reproduction: modeling the end of the germline. Annu. Rev. Physiol. 74, 503-528 (2012).
5. Meng, X. M., Nikolic-Paterson, D. J. & Lan, H. Y. TGF-beta: the master regulator of fibrosis. Nat. Rev. Nephrol. 12, 325-338 (2016).
6. Salazar, V. S., Gamer, L. W. & Rosen, V. BMP signalling in skeletal development, disease and repair. Nat. Rev. Endocrinol. 12, 203-221 (2016).
7. van der Kraan, P. M. The changing role of TGFbeta in healthy, ageing and osteoarthritic joints. Nat. Rev. Rheumatol 13, 155-163 (2017).
8. Cai, J., Pardali, E., Sanchez-Duffhues, G. & ten Dijke, P. BMP signaling in vascular diseases. FEBS Lett. 586, 1993-2002 (2012).
9. Massagué, J. TGFbeta in cancer. Cell 134, 215-230 (2008).
10. Pickup, M., Novitskiy, S. & Moses, H. L. The roles of TGFbeta in the tumour microenvironment. Nat. Rev. Cancer 13, 788-799 (2013).
11. Tauriello, D. V. F. & Batlle, E. Targeting the microenvironment in advanced colorectal cancer. Trends Cancer 2, 495-504 (2016).
12. Wakefield, L. M. & Hill, C. S. Beyond TGFbeta: roles of other TGFbeta superfamily members in cancer. Nat. Rev. Cancer 13, 328-341 (2013).
13. Massagué, J. TGFbeta signalling in context. Nat. Rev. Mol. Cell Biol. 13, 616-630 (2012).
14. Mullen, A. C. & Wrana, J. L. TGF-beta family signaling in embryonic and somatic stem-cell renewal and differentiation. Cold Spring Harb. Perspect. Biol. 9, a022186 (2017).
15. Oshimori, N. & Fuchs, E. The harmonies played by TGF-beta in stem cell biology. Cell Stem Cell 11, 751-764 (2012).
16. Pauklin, S. & Vallier, L. Activin/Nodal signalling in stem cells. Development 142, 607-619 (2015).
17. Chen, W. & Ten Dijke, P. Immunoregulation by members of the TGFbeta superfamily. Nat. Rev. Immunol. 16, 723-740 (2016).
18. Sanjabi, S., Oh, S. A. & Li, M. O. Regulation of the immune response by TGF-beta: from conception to autoimmunity and infection. Cold Spring Harb. Perspect. Biol. 9, a022236 (2017).
19. Shi, Y. & Massagué, J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113, 685-700 (2003).
20. Wrana, J. L. et al. TGF beta signals through a heteromeric protein kinase receptor complex. Cell 71, 1003-1014 (1992).
21. Wrana, J. L., Attisano, L., Wieser, R., Ventura, F. & Massagué, J. Mechanism of activation of the TGF-beta receptor. Nature 370, 341-347 (1994).
22. Inman, G. J., Nicolas, F. J. & Hill, C. S. Nucleocytoplasmic shuttling of Smads 2, 3, and 4 permits sensing of TGF-beta receptor activity. Mol. Cell 10, 283-294 (2002).
23. Xu, L., Kang, Y., Col, S. & Massague, J. Smad2 nucleocytoplasmic shuttling by nucleoporins CAN/Nup214 and Nup153 feeds TGFbeta signaling complexes in the cytoplasm and nucleus. Mol. Cell 10, 271-282 (2002).
24. Martin-Malpartida, P. et al. Structural basis for genome wide recognition of 5-bp GC motifs by SMAD transcription factors. Nat. Commun. 8, 2070 (2017).
25. Hinck, A. P., Mueller, T. D. & Springer, T. A. Structural biology and evolution of the TGF-beta family. Cold Spring Harb. Perspect. Biol. 8, a022103 (2016).
26. Macias, M. J., Martin-Malpartida, P. & Massagué, J. Structural determinants of Smad function in TGF-beta signaling. Trends Biochem. Sci. 40, 296-308 (2015).
27. Nolan, K. & Thompson, T. B. The DAN family: modulators of TGF-beta signaling and beyond. Protein Sci. 23, 999-1012 (2014).
28. Hata, A. & Chen, Y. G. TGF-beta signaling from receptors to Smads. Cold Spring Harb. Perspect. Biol. 8, a022061 (2016).
29. Lamouille, S. & Derynck, R. Emergence of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin axis in transforming growth factor-betainduced epithelial-mesenchymal transition. Cells Tissues Organs 193, 8-22 (2011).
30. Heldin, C. H. & Moustakas, A. Signaling receptors for TGF-beta family members. Cold Spring Harb. Perspect. Biol. 8, a022053 (2016).
31. Mullen, A. C. et al. Master transcription factors determine cell-type-specific responses to TGF-beta signaling. Cell 147, 565-576 (2011).
32. Sun, L. T. et al. Nanog co-regulated by Nodal/Smad2 and Oct4 is required for pluripotency in developing mouse epiblast. Dev. Biol. 392, 182-192 (2014).
33. Wang, W. et al. Smad2 and Smad3 regulate chondrocyte proliferation and differentiation in the growth plate. PLoS Genet. 12, e1006352 (2016).
34. Seoane, J., Le, H. V., Shen, L., Anderson, S. A. & Massagué, J. Integration of Smad and forkhead pathways in the control of neuroepithelial and glioblastoma cell proliferation. Cell 117, 211-223 (2004).
35. Chen, C. R., Kang, Y., Siegel, P. M. & Massague, J. E2F4/5 and p107 as Smad cofactors linking the TGFbeta receptor to c-myc repression. Cell 110, 19-32 (2002).
36. Bardeesy, N. et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev. 20, 3130-3146 (2006).
37. Guasch, G. et al. Loss of TGFbeta signaling destabilizes homeostasis and promotes squamous cell carcinomas in stratified epithelia. Cancer Cell 12, 313-327 (2007).
38. David, C. J. et al. TGF-beta tumor suppression through a lethal EMT. Cell 164, 1015-1030 (2016).
39. Kang, Y. et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl Acad. Sci. USA 102, 13909-13914 (2005).
40. Sethi, N., Dai, X., Winter, C. G. & Kang, Y. Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell 19, 192-205 (2011).
41. Bisgrove, B. W., Su, Y. C. & Yost, H. J. Maternal Gdf3 is an obligatory cofactor in Nodal signaling for embryonic axis formation in zebrafish. eLife 6, e28534 (2017).
42. Montague, T. G. & Schier, A. F. Vg1-Nodal heterodimers are the endogenous inducers of mesendoderm. eLife 6, e28183 (2017).
43. Pelliccia, J. L., Jindal, G. A. & Burdine, R. D. Gdf3 is required for robust Nodal signaling during germ layer formation and left-right patterning. eLife 6, e28635 (2017).
44. Brazil, D. P., Church, R. H., Surae, S., Godson, C. & Martin, F. BMP signalling: agony and antagony in the family. Trends Cell Biol. 25, 249-264 (2015).
45. Wang, R. N. et al. Bone Morphogenetic Protein (BMP) signaling in development and human diseases. Genes Dis. 1, 87-105 (2014).
46. Cheifetz, S. et al. The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell 48, 409-415 (1987).
47. Ling, N. et al. Pituitary FSH is released by a heterodimer of the beta-subunits from the two forms of inhibin. Nature 321, 779-782 (1986).
48. Little, S. C. & Mullins, M. C. Bone morphogenetic protein heterodimers assemble heteromeric type I receptor complexes to pattern the dorsoventral axis. Nat. Cell Biol. 11, 637-643 (2009).
49. Shimmi, O., Umulis, D., Othmer, H. & O'Connor, M. B. Facilitated transport of a Dpp/Scw heterodimer by Sog/Tsg leads to robust patterning of the Drosophila blastoderm embryo. Cell 120, 873-886 (2005).
50. Ozdamar, B. et al. Regulation of the polarity protein Par6 by TGFbeta receptors controls epithelial cell plasticity. Science 307, 1603-1609 (2005).
51. Kashima, R. et al. Augmented noncanonical BMP type II receptor signaling mediates the synaptic abnormality of fragile X syndrome. Sci. Signal 9, ra58 (2016).
52. Lee-Hoeflich, S. T. et al. Activation of LIMK1 by binding to the BMP receptor, BMPRII, regulates BMP-dependent dendritogenesis. EMBO J. 23, 4792-4801 (2004).
53. Hsiung, F., Ramirez-Weber, F. A., Iwaki, D. D. & Kornberg, T. B. Dependence of Drosophila wing imaginal disc cytonemes on Decapentaplegic. Nature 437, 560-563 (2005).
54. Kicheva, A. et al. Kinetics of morphogen gradient formation. Science 315, 521-525 (2007).
55. Keller, B. et al. Interaction of TGFbeta and BMP signaling pathways during chondrogenesis. PLoS ONE 6, e16421 (2011).
56. Klammert, U. et al. GDF-5 can act as a context-dependent BMP-2 antagonist. BMC Biol. 13, 77 (2015).
57. Piscione, T. D. et al. BMP-2 and OP-1 exert direct and opposite effects on renal branching morphogenesis. Am. J. Physiol. 273, F961-975 (1997).
58. Ying, Y., Qi, X. & Zhao, G. Q. Induction of primordial germ cells from murine epiblasts by synergistic action of BMP4 and BMP8B signaling pathways. Proc. Natl Acad. Sci. USA 98, 7858-7862 (2001).
59. Antebi, Y. E. et al. Combinatorial signal perception in the BMP pathway. Cell 170, 1184-1196.e24 (2017).
60. Xi, Q. et al. A poised chromatin platform for TGF-beta access to master regulators. Cell 147, 1511-1524 (2011).
61. Feng, X. H., Zhang, Y., Wu, R. Y. & Derynck, R. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation. Genes Dev. 12, 2153-2163 (1998).
62. Janknecht, R., Wells, N. J. & Hunter, T. TGF-betastimulated cooperation of smad proteins with the coactivators CBP/p300. Genes Dev. 12, 2114-2119 (1998).
63. Pouponnot, C., Jayaraman, L. & Massague, J. Physical and functional interaction of SMADs and p300/CBP. J. Biol. Chem. 273, 22865-22868 (1998).
64. Wotton, D., Lo, R. S., Lee, S. & Massagué, J. A. Smad transcriptional corepressor. Cell 97, 29-39 (1999).
65. Kretzschmar, M., Doody, J. & Massague, J. Opposing BMP and EGF signalling pathways converge on the TGF-beta family mediator Smad1. Nature 389, 618-622 (1997).
66. Pera, E. M., Ikeda, A., Eivers, E. & De Robertis, E. M. Integration of IGF, FGF, and anti-BMP signals via Smad1 phosphorylation in neural induction. Genes Dev. 17, 3023-3028 (2003).
67. Sapkota, G., Alarcon, C., Spagnoli, F. M., Brivanlou, A. H. & Massague, J. Balancing BMP signaling through integrated inputs into the Smad1 linker. Mol. Cell 25, 441-454 (2007).
68. Alarcon, C. et al. Nuclear CDKs drive Smad transcriptional activation and turnover in BMP and TGF-beta pathways. Cell 139, 757-769 (2009).
69. Aragon, E. et al. A Smad action turnover switch operated by WW domain readers of a phosphoserine code. Genes Dev. 25, 1275-1288 (2011).
70. Gao, S. et al. Ubiquitin ligase Nedd4L targets activated Smad2/3 to limit TGF-beta signaling. Mol. Cell 36, 457-468 (2009).
71. Matsuura, I. et al. Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 430, 226-231 (2004).
72. Fuentealba, L. C. et al. Integrating patterning signals: Wnt/GSK3 regulates the duration of the BMP/Smad1 signal. Cell 131, 980-993 (2007).
73. Tsukamoto, S. et al. Smad9 is a new type of transcriptional regulator in bone morphogenetic protein signaling. Sci. Rep. 4, 7596 (2014).
74. Wiater, E. & Vale, W. Roles of activin family in pancreatic development and homeostasis. Mol. Cell Endocrinol. 359, 23-29 (2012).
75. Bruce, D. L. & Sapkota, G. P. Phosphatases in SMAD regulation. FEBS Lett. 586, 1897-1905 (2012).
76. Dong, X. et al. Force interacts with macromolecular structure in activation of TGF-beta. Nature 542, 55-59 (2017).
77. Dupont, S., Inui, M. & Newfeld, S. J. Regulation of TGF-beta signal transduction by mono- and deubiquitylation of Smads. FEBS Lett. 586, 1913-1920 (2012).
78. Herhaus, L. & Sapkota, G. P. The emerging roles of deubiquitylating enzymes (DUBs) in the TGFbeta and BMP pathways. Cell Signal 26, 2186-2192 (2014).
79. Luo, K. Ski and SnoN: negative regulators of TGF-beta signaling. Curr. Opin. Genet. Dev. 14, 65-70 (2004).
80. Miyazawa, K. & Miyazono, K. Regulation of TGF-beta family signaling by inhibitory Smads. Cold Spring Harb. Perspect. Biol. 9, a022095 (2017).
81. Parrow, N. L. & Fleming, R. E. Bone morphogenetic proteins as regulators of iron metabolism. Annu. Rev. Nutr. 34, 77-94 (2014).
82. Saito, T. et al. Structural basis of the human endoglin-BMP9 interaction: insights into BMP signaling and HHT1. Cell Rep. 19, 1917-1928 (2017).
83. Siebold, C., Yamashita, T., Monnier, P. P., Mueller, B. K. & Pasterkamp, R. J. RGMs: structural insights, molecular regulation, and downstream signaling. Trends Cell Biol 27, 365-378 (2017).
84. Pirruccello-Straub, M. et al. Blocking extracellular activation of myostatin as a strategy for treating muscle wasting. Sci. Rep. 8, 2292 (2018).
85. Roberts, A. B. et al. Type beta transforming growth factor: a bifunctional regulator of cellular growth. Proc. Natl Acad. Sci. USA 82, 119-123 (1985).
86. Tucker, R. F., Shipley, G. D., Moses, H. L. & Holley, R. W. Growth inhibitor from BSC-1 cells closely related to platelet type beta transforming growth factor. Science 226, 705-707 (1984).
87. Ohta, M., Greenberger, J. S., Anklesaria, P., Bassols, A. & Massagué, J. Two forms of transforming growth factor-beta distinguished by multipotential haematopoietic progenitor cells. Nature 329, 539-541 (1987).
88. Sporn, M. B. et al. Polypeptide transforming growth factors isolated from bovine sources and used for wound healing in vivo. Science 219, 1329-1331 (1983).
89. Zawel, L. et al. Human Smad3 and Smad4 are sequence-specific transcription activators. Mol. Cell 1, 611-617 (1998).
90. Shi, Y. et al. Crystal structure of a Smad MH1 domain bound to DNA: insights on DNA binding in TGF-beta signaling. Cell 94, 585-594 (1998).
91. Babu Rajendran, N. et al. Structure of Smad1 MH1/DNA complex reveals distinctive rearrangements of BMP and TGF-beta effectors. Nucleic Acids Res. 38, 3477-3488 (2010).
92. Kusanagi, K. et al. Characterization of a bone morphogenetic protein-responsive Smad-binding element. Mol. Biol. Cell 11, 555-565 (2000).
93. Labbe, E., Silvestri, C., Hoodless, P. A., Wrana, J. L. & Attisano, L. Smad2 and Smad3 positively and negatively regulate TGF beta-dependent transcription through the forkhead DNA-binding protein FAST2. Mol. Cell 2, 109-120 (1998).
94. Morikawa, M. et al. ChIP-seq reveals cell type-specific binding patterns of BMP-specific Smads and a novel binding motif. Nucleic Acids Res. 39, 8712-8727 (2011).
95. Wang, Q. et al. The p53 family coordinates Wnt and nodal Inputs in mesendodermal differentiation of embryonic stem cells. Cell Stem Cell 20, 70-86 (2017).
96. Yoon, S. J., Foley, J. W. & Baker, J. C. HEB associates with PRC2 and SMAD2/3 to regulate developmental fates. Nat. Commun. 6, 6546 (2015).
97. Zhang, D. X. & Glass, C. K. Towards an understanding of cell-specific functions of signal-dependent transcription factors. J. Mol. Endocrinol. 51, T37-50 (2013).
98. Chen, X., Rubock, M. J. & Whitman, M. A transcriptional partner for MAD proteins in TGF-beta signalling. Nature 383, 691-696 (1996).
99. Chen, X. et al. Smad4 and FAST-1 in the assembly of activin-responsive factor. Nature 389, 85-89 (1997).
100. Hata, A. et al. OAZ uses distinct DNA- and protein-binding zinc fingers in separate BMP-Smad and Olf signaling pathways. Cell 100, 229-240 (2000).
101. Trompouki, E. et al. Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regeneration. Cell 147, 577-589 (2011).
102. Attisano, L. & Wrana, J. L. Signal integration in TGF-beta, WNT, and Hippo pathways. F1000Prime Rep. 5, 17 (2013).
103. Guo, X. & Wang, X. F. Signaling cross-talk between TGF-beta/BMP and other pathways. Cell Res. 19, 71-88 (2009).
104. Qing, J., Zhang, Y. & Derynck, R. Structural and functional characterization of the transforming growth factor-beta-induced Smad3/c-Jun transcriptional cooperativity. J. Biol. Chem. 275, 38802-38812 (2000).
105. Park, S. R., Seo, G. Y., Choi, A. J., Stavnezer, J. & Kim, P. H. Analysis of transforming growth factor-beta1-induced Ig germ-line gamma2b transcription and its implication for IgA isotype switching. Eur. J. Immunol. 35, 946-956 (2005).
106. Kang, Y., Chen, C. R. & Massagué, J. A self-enabling TGFbeta response coupled to stress signaling: Smad engages stress response factor ATF3 for Id1 repression in epithelial cells. Mol. Cell 11, 915-926 (2003).
107. Hnisz, D. et al. Super-enhancers in the control of cell identity and disease. Cell 155, 934-947 (2013).
108. Whyte, W. A. et al. Master transcription factors and mediator establish super-enhancers at key cell identity genes. Cell 153, 307-319 (2013).
109. Hnisz, D. et al. Convergence of developmental and oncogenic signaling pathways at transcriptional super-enhancers. Mol. Cell 58, 362-370 (2015).
110. Loose, M. & Patient, R. A genetic regulatory network for Xenopus mesendoderm formation. Dev. Biol. 271, 467-478 (2004).
111. Gaarenstroom, T. & Hill, C. S. TGF-beta signaling to chromatin: how Smads regulate transcription during self-renewal and differentiation. Semin. Cell Dev. Biol. 32, 107-118 (2014).
112. Charney, R. M. et al. Foxh1 Occupies cis-Regulatory Modules Prior to Dynamic Transcription Factor Interactions Controlling the Mesendoderm Gene Program. Dev. Cell 40, 595-607.e4 (2017).
113. Kim, S. W. et al. Chromatin and transcriptional signatures for Nodal signaling during endoderm formation in hESCs. Dev. Biol. 357, 492-504 (2011).
114. Nelson, A. C. et al. In vivo regulation of the zebrafish endoderm progenitor niche by T-box transcription factors. Cell Rep. 19, 2782-2795 (2017).
115. Coda, D. M. et al. Distinct modes of SMAD2 chromatin binding and remodeling shape the transcriptional response to NODAL/Activin signaling. eLife 6, e22474 (2017).
116. Dupont, S. et al. Germ-layer specification and control of cell growth by Ectodermin, a Smad4 ubiquitin ligase. Cell 121, 87-99 (2005).
117. Genander, M. et al. BMP signaling and its pSMAD1/5 target genes differentially regulate hair follicle stem cell lineages. Cell Stem Cell 15, 619-633 (2014).
118. Hwang, J., Mehrani, T., Millar, S. E. & Morasso, M. I. Dlx3 is a crucial regulator of hair follicle differentiation and cycling. Development 135, 3149-3159 (2008).
119. Faial, T. et al. Brachyury and SMAD signalling collaboratively orchestrate distinct mesoderm and endoderm gene regulatory networks in differentiating human embryonic stem cells. Development 142, 2121-2135 (2015).
120. Izzi, L. et al. Foxh1 recruits Gsc to negatively regulate Mixl1 expression during early mouse development. EMBO J. 26, 3132-3143 (2007).
121. Teo, A. K. et al. Pluripotency factors regulate definitive endoderm specification through eomesodermin. Genes Dev. 25, 238-250 (2011).
122. Germain, S., Howell, M., Esslemont, G. M. & Hill, C. S. Homeodomain and winged-helix transcription factors recruit activated Smads to distinct promoter elements via a common Smad interaction motif. Genes Dev. 14, 435-451 (2000).
123. Sancho, E., Batlle, E. & Clevers, H. Signaling pathways in intestinal development and cancer. Annu. Rev. Cell Dev. Biol. 20, 695-723 (2004).
124. Watabe, T. et al. Molecular mechanisms of Spemann's organizer formation: conserved growth factor synergy between Xenopus and mouse. Genes Dev. 9, 3038-3050 (1995).
125. Reid, C. D., Zhang, Y., Sheets, M. D. & Kessler, D. S. Transcriptional integration of Wnt and Nodal pathways in establishment of the Spemann organizer. Dev. Biol. 368, 231-241 (2012).
126. Stevens, M. L. et al. Genomic integration of Wnt/beta-catenin and BMP/Smad1 signaling coordinates foregut and hindgut transcriptional programs. Development 144, 1283-1295 (2017).
127. Shigeta, M. et al. Maintenance of pluripotency in mouse ES cells without Trp53. Sci. Rep. 3, 2944 (2013).
128. Cordenonsi, M. et al. Links between tumor suppressors: p53 is required for TGF-beta gene responses by cooperating with Smads. Cell 113, 301-314 (2003).
129. Wallingford, J. B., Seufert, D. W., Virta, V. C. & Vize, P. D. p53 activity is essential for normal development in Xenopus. Curr. Biol. 7, 747-757 (1997).
130. Beyer, T. A. et al. Switch enhancers interpret TGF-beta and Hippo signaling to control cell fate in human embryonic stem cells. Cell Rep. 5, 1611-1624 (2013).
131. Estaras, C., Benner, C. & Jones, K. A. SMADs and YAP compete to control elongation of beta-catenin:LEF-1-recruited RNAPII during hESC differentiation. Mol. Cell 58, 780-793 (2015).
132. Varelas, X. et al. The Crumbs complex couples cell density sensing to Hippo-dependent control of the TGF-beta-SMAD pathway. Dev. Cell 19, 831-844 (2010).
133. Singh, A. M. et al. Signaling network crosstalk in human pluripotent cells: a Smad2/3-regulated switch that controls the balance between self-renewal and differentiation. Cell Stem Cell 10, 312-326 (2012).
134. Omata, Y. et al. Genomewide comprehensive analysis reveals critical cooperation between Smad and c-Fos in RANKL-induced osteoclastogenesis. J. Bone Miner. Res. 30, 869-877 (2015).
135. Nieto, M. A., Huang, R. Y., Jackson, R. A. & Thiery, J. P. Emt: 2016. Cell 166, 21-45 (2016).
136. Miettinen, P. J., Ebner, R., Lopez, A. R. & Derynck, R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J. Cell Biol. 127, 2021-2036 (1994).
137. Oft, M. et al. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 10, 2462-2477 (1996).
138. Moustakas, A. & Heldin, C. H. Mechanisms of TGFbeta-induced epithelial-mesenchymal transition. J. Clin. Med. 5, 63 (2016).
139. Yang, J. & Weinberg, R. A. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev. Cell 14, 818-829 (2008).
140. Boyer, A. S. et al. TGFbeta2 and TGFbeta3 have separate and sequential activities during epithelial-mesenchymal cell transformation in the embryonic heart. Dev. Biol. 208, 530-545 (1999).
141. Romano, L. A. & Runyan, R. B. Slug is an essential target of TGFbeta2 signaling in the developing chicken heart. Dev. Biol. 223, 91-102 (2000).
142. Oshimori, N., Oristian, D. & Fuchs, E. TGF-beta promotes heterogeneity and drug resistance in squamous cell carcinoma. Cell 160, 963-976 (2015).
143. Puram, S. V. et al. Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in head and neck cancer. Cell 171, 1611-1624.e24 (2017).
144. Ye, X. & Weinberg, R. A. Epithelial-mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol. 25, 675-686 (2015).
145. Gotzmann, J. et al. Hepatocytes convert to a fibroblastoid phenotype through the cooperation of TGF-beta1 and Ha-Ras: steps towards invasiveness. J. Cell Sci. 115, 1189-1202 (2002).
146. Oft, M., Akhurst, R. J. & Balmain, A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat. Cell Biol. 4, 487-494 (2002).
147. Horiguchi, K. et al. Role of Ras signaling in the induction of snail by transforming growth factor-beta. J. Biol. Chem. 284, 245-253 (2009).
148. Peinado, H., Quintanilla, M. & Cano, A. Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J. Biol. Chem. 278, 21113-21123 (2003).
149. Stritesky, G. L., Jameson, S. C. & Hogquist, K. A. Selection of self-reactive T cells in the thymus. Annu. Rev. Immunol. 30, 95-114 (2012).
150. Brabletz, T. et al. Transforming growth factor beta and cyclosporin A inhibit the inducible activity of the interleukin-2 gene in T cells through a noncanonical octamer-binding site. Mol. Cell. Biol. 13, 1155-1162 (1993).
151. Thomas, D. A. & Massagué, J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 8, 369-380 (2005).
152. Budhu, S. et al. Blockade of surface-bound TGF-beta on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment. Sci. Signal. 10, eaak9702 (2017).
153. Josefowicz, S. Z., Lu, L. F. & Rudensky, A. Y. Regulatory T cells: mechanisms of differentiation and function. Annu. Rev. Immunol. 30, 531-564 (2012).
154. Hori, S., Nomura, T. & Sakaguchi, S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299, 1057-1061 (2003).
155. Chen, W. et al. Conversion of peripheral CD4 + CD25-naive T cells to CD4 + CD25 + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J. Exp. Med. 198, 1875-1886 (2003).
156. Tone, Y. et al. Smad3 and NFAT cooperate to induce Foxp3 expression through its enhancer. Nat. Immunol. 9, 194-202 (2008).
157. Wu, C. et al. The transcription factor musculin promotes the unidirectional development of peripheral Treg cells by suppressing the TH2 transcriptional program. Nat. Immunol. 18, 344-353 (2017).
158. Ouyang, W., Beckett, O., Ma, Q. & Li, M. O. Transforming growth factor-beta signaling curbs thymic negative selection promoting regulatory T cell development. Immunity 32, 642-653 (2010).
159. Zhou, L. et al. TGF-beta-induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 453, 236-240 (2008).
160. Ivanov, I. I. et al. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17 + T helper cells. Cell 126, 1121-1133 (2006).
161. Takimoto, T. et al. Smad2 and Smad3 are redundantly essential for the TGF-beta-mediated regulation of regulatory T plasticity and Th1 development. J. Immunol. 185, 842-855 (2010).
162. Martinez, G. J. et al. Smad2 positively regulates the generation of Th17 cells. J. Biol. Chem. 285, 29039-29043 (2010).
163. Gorelik, L., Constant, S. & Flavell, R. A. Mechanism of transforming growth factor beta-induced inhibition of T helper type 1 differentiation. J. Exp. Med. 195, 1499-1505 (2002).
164. Kuwahara, M. et al. The transcription factor Sox4 is a downstream target of signaling by the cytokine TGF-beta and suppresses T(H)2 differentiation. Nat. Immunol. 13, 778-786 (2012).
165. Markowitz, S. et al. Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science 268, 1336-1338 (1995).
166. Hahn, S. A. et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271, 350-353 (1996).
167. Shi, Y., Hata, A., Lo, R. S., Massagué, J. & Pavletich, N. P. A structural basis for mutational inactivation of the tumour suppressor Smad4. Nature 388, 87-93 (1997).
168. Zorn, A. M. & Wells, J. M. Vertebrate endoderm development and organ formation. Annu. Rev. Cell Dev. Biol. 25, 221-251 (2009).
169. Ijichi, H. et al. Aggressive pancreatic ductal adenocarcinoma in mice caused by pancreas-specific blockade of transforming growth factor-beta signaling in cooperation with active Kras expression. Genes Dev. 20, 3147-3160 (2006).
170. Hannon, G. J. & Beach, D. p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371, 257-261 (1994).
171. Polyak, K. et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78, 59-66 (1994).
172. Reynisdóttir, I., Polyak, K., Iavarone, A. & Massagué, J. Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. Genes Dev. 9, 1831-1845 (1995).
173. Scandura, J. M., Boccuni, P., Massagué, J. & Nimer, S. D. Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation. Proc. Natl Acad. Sci. USA 101, 15231-15236 (2004).
174. Ding, Z. et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470, 269-273 (2011).
175. Bjerke, G. A., Yang, C. S., Frierson, H. F., Paschal, B. M. & Wotton, D. Activation of Akt signaling in prostate induces a TGFbeta-mediated restraint on cancer progression and metastasis. Oncogene 33, 3660-3667 (2014).
176. Nandan, M. O., Ghaleb, A. M., Bialkowska, A. B. & Yang, V. W. Kruppel-like factor 5 is essential for proliferation and survival of mouse intestinal epithelial stem cells. Stem Cell Res. 14, 10-19 (2015).
177. Diaferia, G. R. et al. Dissection of transcriptional and cis-regulatory control of differentiation in human pancreatic cancer. EMBO J. 35, 595-617 (2016).
178. Zhang, B. et al. KLF5 activates microRNA 200 transcription to maintain epithelial characteristics and prevent induced epithelial-mesenchymal transition in epithelial cells. Mol. Cell. Biol. 33, 4919-4935 (2013).
179. Chia, N. Y. et al. Regulatory crosstalk between lineage-survival oncogenes KLF5, GATA4 and GATA6 cooperatively promotes gastric cancer development. Gut 64, 707-719 (2015).
180. Tan, T. Z. et al. Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. EMBO Mol. Med. 6, 1279-1293 (2014).
181. Gal, A. et al. Sustained TGF beta exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis. Oncogene 27, 1218-1230 (2008).
182. Ryan, D. P., Hong, T. S. & Bardeesy, N. Pancreatic adenocarcinoma. N. Engl. J. Med. 371, 1039-1049 (2014).
183. Friess, H. et al. Enhanced expression of transforming growth factor beta isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 105, 1846-1856 (1993).
184. Wagner, M., Kleeff, J., Friess, H., Buchler, M. W. & Korc, M. Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. Pancreas 19, 370-376 (1999).
185. Diepenbruck, M. & Christofori, G. Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe? Curr. Opin. Cell Biol. 43, 7-13 (2016).
186. Tiwari, N. et al. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell 23, 768-783 (2013).
187. Penuelas, S. et al. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 15, 315-327 (2009).
188. Padua, D. et al. TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133, 66-77 (2008).
189. Kakonen, S. M. et al. Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J. Biol. Chem. 277, 24571-24578 (2002).
190. Massague, J. & Obenauf, A. C. Metastatic colonization by circulating tumour cells. Nature 529, 298-306 (2016).
191. Malladi, S. et al. Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT. Cell 165, 45-60 (2016).
192. Calon, A. et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47, 320-329 (2015).
193. Calon, A. et al. Dependency of colorectal cancer on a TGF-beta-driven program in stromal cells for metastasis initiation. Cancer Cell 22, 571-584 (2012).
194. Tauriello, D. V. F. et al. TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis. Nature 554, 538-543 (2018).
195. Mariathasan, S. et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554,544-548 (2018).